Tuesday, July 12, 2022

Biotech Can't Conquer the Lungs. Will These Stocks Succeed? - TheStreet

Unlike AAV gene therapy, HSV gene therapy doesn't trigger immune responses, which means it can be dosed in perpetuity.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

2 muggers captured by RU students on campus - UNB

Rayhanul Ferdous, a student of Genetic Engineering and Biotechnology department who had his phone stolen told UNB: “I was walking on the eas...